The GLP-1 Question Every Client Is Asking: A Broker Playbook

Every renewal meeting this year includes some version of the same question: "What do we do about GLP-1s?" Most brokers don't have a good answer yet — which means the broker who does walks into every meeting with an advantage. Here's the framework: the four answers clients are hearing, why three of them fail, and how to present the fourth.

The Bind Your Clients Are In

GLP-1 demand isn't a fad your clients can wait out. Employees are asking for coverage by name, comparing employers on it, and in some cases leaving over it. At the same time, list prices in the four figures per month mean that uncapped coverage for even a modest share of a population can move the entire medical trend line.

So your client is squeezed between two bad headlines: "we don't cover the drug everyone wants" and "our premiums jumped double digits because of one drug class." Neither is a benefits strategy. Your job is to give them a third option — and to be the advisor who framed the problem before the client's employees or their CFO did.

The Four Answers Clients Hear

When a client shops this question around, they'll hear four answers. Walk them through all four honestly — conceding what's true about each is what makes the recommendation credible.

1. Cover It Uncapped on the Medical Plan

The simplest answer, and the most expensive. Uncapped pharmacy coverage means the employer absorbs open-ended cost with no ceiling and no lever except prior-authorization friction — which employees experience as denial by paperwork. For most small and mid-market groups, the carrier or PBM math on this is brutal at renewal. It's the right answer for a handful of well-funded groups that have decided GLP-1 access is a core recruiting weapon; it's a budget grenade for everyone else.

2. Exclude It Entirely

Cheap, clean, and increasingly untenable. Exclusion pushes the cost problem onto employees, who then pay cash, chase compounded alternatives, or quietly resent the benefit plan. It also gives your client nothing to say in offer letters and open enrollment. Exclusion is defensible as a temporary posture, not a destination — and clients know it, which is why they're asking you.

3. A Cash Stipend

Some employers try to split the difference: "we'll give employees $300 a month toward the drug." This is the option that sounds reasonable and is actually the most dangerous. A stipend earmarked for a medical expense can be treated as an employer payment plan for medical care — a group health plan — pulling in ERISA, ACA, and COBRA obligations the stipend was never structured to meet. It's also taxable income, so a meaningful slice of every dollar evaporates before it reaches the pharmacy. Flag this one clearly for clients (and suggest they confirm with benefits counsel): an HRA is itself a group health plan — the difference is that it's a recognized structure built to meet those obligations, while an earmarked stipend triggers them with nothing in place to satisfy them.

4. A Capped Specialty HRA

The answer that actually resolves the bind: a capped, employer-defined, tax-free allowance for GLP-1s, run as a Specialty HRA. The employer picks the number — that's the whole point. Cost is fixed and budgetable, the benefit is real and nameable, and the dollars are tax-free rather than taxed as wages.

How the Specialty HRA Works in Practice

The mechanics matter, because your client's next questions will be about HSA eligibility and how employees actually fill prescriptions:

• Employees fill through manufacturer-direct cash-pay programs, which have brought cash prices well below list. The HRA allowance stacks on top of those programs, so a capped employer contribution covers more of the real price than the list price suggests.
• The design preserves HSA eligibility alongside HDHPs. This is the trap in most first-draft designs — first-dollar drug coverage can disqualify employees from HSA contributions. A properly structured Specialty HRA is designed to avoid that, which matters for any client where you've built an HSA strategy.
• For PPO populations, the HRA pairs with HRA-pays-first ordering, so the allowance applies before employee cost-sharing.
• There's no PBM and no prescribing involved. The employer isn't practicing medicine or negotiating rebates — it's funding a defined allowance against a defined expense.

For a fuller employer-side treatment you can hand to clients, see our GLP-1 benefit strategy guide.

Positioning Yourself as the Broker With an Answer

Raise this before the client does. A one-page comparison — the four options, cost exposure, compliance exposure, employee experience — turns "we should talk about GLP-1s" into a concrete decision at renewal instead of a panic mid-year. The brokers winning new groups on this aren't the ones with the cheapest spreadsheet; they're the ones who showed up with a framework while the incumbent was still saying "we're monitoring the space."

How Hammock Helps

Hammock administers GLP-1 Specialty HRAs end to end: plan documents, claims adjudication, and compliance, with the cap set wherever your client wants it. The design is built to preserve HSA eligibility next to HDHPs and to pair with PPOs using HRA-pays-first ordering — no PBM contract, no prescribing.

For brokers, that means you bring the answer and Hammock does the administrative work, with a dedicated account manager and white-glove support so your team isn't fielding claims questions.

FAQ

Why is a cash stipend for GLP-1s risky?

A stipend directed at a specific medical expense can be treated as a group health plan, triggering ERISA, ACA, and COBRA obligations it wasn't built to meet — and it's taxable income besides. A properly structured HRA delivers the same dollars tax-free through a structure actually built to meet those obligations. Worth confirming specifics with benefits counsel.

Does a GLP-1 HRA break HSA eligibility?

It can if it's designed carelessly — first-dollar medical coverage generally disqualifies HSA contributions. Hammock's Specialty HRA is specifically designed to preserve HSA eligibility alongside HDHPs.

How does the employer control cost?

The cap is employer-defined. The employer sets a monthly or annual allowance, and that's the maximum exposure — unlike uncapped pharmacy coverage, where utilization sets the bill.

What should I bring to the client meeting?

A four-option comparison: uncapped coverage, exclusion, cash stipend, capped Specialty HRA — with cost exposure, compliance exposure, and employee experience for each. Lead with the bind, concede the tradeoffs, recommend the structure that fixes both headlines.

The Bottom Line

Every client is going to answer the GLP-1 question this cycle — the only variable is whether they answer it with you or around you. Uncapped coverage blows up the budget, exclusion blows up the message, and cash stipends blow up quietly in compliance. A capped Specialty HRA is the option that gives your client a real benefit at a fixed, chosen cost.

Ready to bring this to your book? Partner with us.